A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

By Sørensen Jan   Stage Kurt   Damsbo Niels   Lay Agathe Le   Hemels Michiel  

Nordic Journal of Psychiatry, Vol. 61, Iss. 2, 2007-01 ,pp. : 100-108

Informa Healthcare

Access to resources Recommend Favorite

Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder

By Xie Feng   Despiegel Nicolas   Danchenko Natalya   Hansen Karina  

International Journal of Psychiatry in Clinical Practice, Vol. 13, Iss. 1, 2009-03 ,pp. : 59-69

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria

By Brown M.C.J.   Nimmerrichter A.A.   Guest J.F.  

European Psychiatry, Vol. 14, Iss. 4, 1999-07 ,pp. : 230-244

Elsevier

Access to resources Recommend Favorite

Thyroid autoimmunity and treatment response to escitalopram in major depression

By Eller Triin   Metsküla Kaja   Talja Ija   Maron Eduard   Uibo Raivo   Vasar Veiko  

Nordic Journal of Psychiatry, Vol. 64, Iss. 4, 2010-08 ,pp. : 253-257

Informa Healthcare

Access to resources Recommend Favorite

Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram

By Lançon Christophe   Verpillat Patrice   Annemans Lieven   Despiegel Nicolas   François Clément  

International Journal of Psychiatry in Clinical Practice, Vol. 11, Iss. 1, 2007-01 ,pp. : 44-52

Ashgate Publishing Ltd

Access to resources Recommend Favorite